Rethinking Survival Metrics in EGFR-Mutated NSCLC: Insights from RMST Analysis of FLAURA2 and MARIPOSA

The introduction of combination regimens in the first-line treatment of epidermal growth factor receptor (EGFR) positive non-small cell lung cancer (NSCLC) is reshaping expectations of long-term survival. In this evolving context, hazard ratios (HRs) derived from proportional hazards (PH) models may not capture the true magnitude of benefit, particularly when survival curves overlap or cross before diverging1,2. Restricted mean survival…